From Cell Culture to Exosomes: Meet The Bio-Trac Instructors Shaping the Life Sciences Landscape Established in 1985 by Mark Nardone and his father, Dr. Roland M. Nardone, Bio-Trac has conducted [….]
Learn from and meet leading experts in pharmaceutical science, addressing the critical strategic advances and technical innovation in formulation, drug delivery, RNA therapeutics & inhaled therapies. The 2024 event will [….]
Join RNA leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the formulation [….]
This 5-Day workshop combines a unique mix of hands-on wet bench and electronic laboratory experiences together with a series of lectures spanning an introduction to the concepts of RNA sequencing [….]
This in-depth lecture and hands-on laboratory workshop (wet lab & in silica) is ideal for those research and bench scientists who are interested in a comprehensive introduction to single cell [….]
This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Developed and taught by active researchers, this workshop will focus on [….]
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.
Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]
